Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression.

The Journal of investigative dermatology

Cao Y, Harvey BP, Hong F, Ruzek M, Wang J, Murphy ER, Kaymakcalan Z.
PMID: 33965402
J Invest Dermatol. 2021 Nov;141(11):2730-2740.e9. doi: 10.1016/j.jid.2021.04.010. Epub 2021 May 31.

Adalimumab (ADA) is the only Food and Drug Administration‒approved treatment for moderate-to-severe hidradenitis suppurativa, whereas etanercept and certolizumab-pegol have been shown to be ineffective, suggesting that the mechanism of action of ADA is distinct in hidradenitis suppurativa and may...

Cite
Cao Y, Harvey BP, Hong F, et al. Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression. J Invest Dermatol. 2021;141(11):2730-2740.e9doi: 10.1016/j.jid.2021.04.010.
Cao, Y., Harvey, B. P., Hong, F., Ruzek, M., Wang, J., Murphy, E. R., & Kaymakcalan, Z. (2021). Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression. The Journal of investigative dermatology, 141(11), 2730-2740.e9. https://doi.org/10.1016/j.jid.2021.04.010
Cao, Yonghao, et al. "Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression." The Journal of investigative dermatology vol. 141,11 (2021): 2730-2740.e9. doi: https://doi.org/10.1016/j.jid.2021.04.010
Cao Y, Harvey BP, Hong F, Ruzek M, Wang J, Murphy ER, Kaymakcalan Z. Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression. J Invest Dermatol. 2021 Nov;141(11):2730-2740.e9. doi: 10.1016/j.jid.2021.04.010. Epub 2021 May 31. PMID: 33965402.
Copy Download .nbib Format: NLM
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.

Journal for immunotherapy of cancer

Fay AP, Signoretti S, Callea M, Telό GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK.
PMID: 25767716
J Immunother Cancer. 2015 Feb 17;3:3. doi: 10.1186/s40425-015-0047-3. eCollection 2015.

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare tumor in which prognostic factors are still not well established. Programmed Death Ligand-1 (PD-L1) expression in ACC and its association with clinico-pathological features and survival outcomes are unknown.METHODS: Formalin-fixed paraffin-embedded (FFPE) specimens...

Cite
Fay AP, Signoretti S, Callea M, et al. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015;3:3doi: 10.1186/s40425-015-0047-3.
Fay, A. P., Signoretti, S., Callea, M., Telό, G. H., McKay, R. R., Song, J., Carvo, I., Lampron, M. E., Kaymakcalan, M. D., Poli-de-Figueiredo, C. E., Bellmunt, J., Hodi, F. S., Freeman, G. J., Elfiky, A., & Choueiri, T. K. (2015). Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. Journal for immunotherapy of cancer, 33. https://doi.org/10.1186/s40425-015-0047-3
Fay, André P, et al. "Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study." Journal for immunotherapy of cancer vol. 3 (2015): 3. doi: https://doi.org/10.1186/s40425-015-0047-3
Fay AP, Signoretti S, Callea M, Telό GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015 Feb 17;3:3. doi: 10.1186/s40425-015-0047-3. eCollection 2015. PMID: 25767716; PMCID: PMC4357210.
Copy Download .nbib Format: NLM
Sternal wound reconstruction with falciform and omental flaps for chronic sternal osteomyelitis.

Plastic and reconstructive surgery. Global open

Levites HA, Kaymakcalan OE, Phillips BT, Bilfinger TV, Dagum AB.
PMID: 25426350
Plast Reconstr Surg Glob Open. 2014 Nov 07;2(10):e233. doi: 10.1097/GOX.0000000000000194. eCollection 2014 Oct.

No abstract available.

Cite
Levites HA, Kaymakcalan OE, Phillips BT, et al. Sternal wound reconstruction with falciform and omental flaps for chronic sternal osteomyelitis. Plast Reconstr Surg Glob Open. 2014;2(10):e233doi: 10.1097/GOX.0000000000000194.
Levites, H. A., Kaymakcalan, O. E., Phillips, B. T., Bilfinger, T. V., & Dagum, A. B. (2014). Sternal wound reconstruction with falciform and omental flaps for chronic sternal osteomyelitis. Plastic and reconstructive surgery. Global open, 2(10), e233. https://doi.org/10.1097/GOX.0000000000000194
Levites, Heather A, et al. "Sternal wound reconstruction with falciform and omental flaps for chronic sternal osteomyelitis." Plastic and reconstructive surgery. Global open vol. 2,10 (2014): e233. doi: https://doi.org/10.1097/GOX.0000000000000194
Levites HA, Kaymakcalan OE, Phillips BT, Bilfinger TV, Dagum AB. Sternal wound reconstruction with falciform and omental flaps for chronic sternal osteomyelitis. Plast Reconstr Surg Glob Open. 2014 Nov 07;2(10):e233. doi: 10.1097/GOX.0000000000000194. eCollection 2014 Oct. PMID: 25426350; PMCID: PMC4236378.
Copy Download .nbib Format: NLM
Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly.

Molecular genetics & genomic medicine

Kaymakcalan H, Kaya İ, Cevher Binici N, Nikerel E, Özbaran B, Görkem Aksoy M, Erbilgin S, Özyurt G, Jahan N, Çelik D, Yararbaş K, Yalçınkaya L, Köse S, Durak S, Ercan-Sencicek AG.
PMID: 34268892
Mol Genet Genomic Med. 2021 Aug;9(8):e1739. doi: 10.1002/mgg3.1739. Epub 2021 Jul 16.

BACKGROUND: Phosphatase and tensin homolog (PTEN) germline mutations are associated with cancer syndromes (PTEN hamartoma tumor syndrome; PHTS) and in pediatric patients with autism spectrum disorder (ASD) and macrocephaly. The exact prevalence of PTEN mutations in patients with ASD...

Cite
Kaymakcalan H, Kaya İ, Cevher Binici N, et al. Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly. Mol Genet Genomic Med. 2021;9(8):e1739doi: 10.1002/mgg3.1739.
Kaymakcalan, H., Kaya, �. �., Cevher Binici, N., Nikerel, E., Özbaran, B., Görkem Aksoy, M., Erbilgin, S., Özyurt, G., Jahan, N., Çelik, D., Yararbaş, K., Yalçınkaya, L., Köse, S., Durak, S., & Ercan-Sencicek, A. G. (2021). Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly. Molecular genetics & genomic medicine, 9(8), e1739. https://doi.org/10.1002/mgg3.1739
Kaymakcalan, Hande, et al. "Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly." Molecular genetics & genomic medicine vol. 9,8 (2021): e1739. doi: https://doi.org/10.1002/mgg3.1739
Kaymakcalan H, Kaya İ, Cevher Binici N, Nikerel E, Özbaran B, Görkem Aksoy M, Erbilgin S, Özyurt G, Jahan N, Çelik D, Yararbaş K, Yalçınkaya L, Köse S, Durak S, Ercan-Sencicek AG. Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly. Mol Genet Genomic Med. 2021 Aug;9(8):e1739. doi: 10.1002/mgg3.1739. Epub 2021 Jul 16. PMID: 34268892; PMCID: PMC8404225.
Copy Download .nbib Format: NLM
Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly.

Molecular genetics & genomic medicine

Kaymakcalan H, Kaya İ, Cevher Binici N, Nikerel E, Özbaran B, Görkem Aksoy M, Erbilgin S, Özyurt G, Jahan N, Çelik D, Yararbaş K, Yalçınkaya L, Köse S, Durak S, Ercan-Sencicek AG.
PMID: 34268892
Mol Genet Genomic Med. 2021 Aug;9(8):e1739. doi: 10.1002/mgg3.1739. Epub 2021 Jul 16.

BACKGROUND: Phosphatase and tensin homolog (PTEN) germline mutations are associated with cancer syndromes (PTEN hamartoma tumor syndrome; PHTS) and in pediatric patients with autism spectrum disorder (ASD) and macrocephaly. The exact prevalence of PTEN mutations in patients with ASD...

Cite
Kaymakcalan H, Kaya İ, Cevher Binici N, et al. Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly. Mol Genet Genomic Med. 2021;9(8):e1739doi: 10.1002/mgg3.1739.
Kaymakcalan, H., Kaya, �. �., Cevher Binici, N., Nikerel, E., Özbaran, B., Görkem Aksoy, M., Erbilgin, S., Özyurt, G., Jahan, N., Çelik, D., Yararbaş, K., Yalçınkaya, L., Köse, S., Durak, S., & Ercan-Sencicek, A. G. (2021). Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly. Molecular genetics & genomic medicine, 9(8), e1739. https://doi.org/10.1002/mgg3.1739
Kaymakcalan, Hande, et al. "Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly." Molecular genetics & genomic medicine vol. 9,8 (2021): e1739. doi: https://doi.org/10.1002/mgg3.1739
Kaymakcalan H, Kaya İ, Cevher Binici N, Nikerel E, Özbaran B, Görkem Aksoy M, Erbilgin S, Özyurt G, Jahan N, Çelik D, Yararbaş K, Yalçınkaya L, Köse S, Durak S, Ercan-Sencicek AG. Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly. Mol Genet Genomic Med. 2021 Aug;9(8):e1739. doi: 10.1002/mgg3.1739. Epub 2021 Jul 16. PMID: 34268892; PMCID: PMC8404225.
Copy Download .nbib Format: NLM
Chiral Lagrangian of pseudoscalars and vectors.

Physical review. D, Particles and fields

Kaymakcalan Ö, Schechter J.
PMID: 9955803
Phys Rev D Part Fields. 1985 Mar 01;31(5):1109-1113. doi: 10.1103/physrevd.31.1109.

No abstract available.

Cite
Kaymakcalan Ö, Schechter J. Chiral Lagrangian of pseudoscalars and vectors. Phys Rev D Part Fields. 1985;31(5):1109-1113doi: 10.1103/physrevd.31.1109.
Kaymakcalan, �. �., & Schechter, J. (1985). Chiral Lagrangian of pseudoscalars and vectors. Physical review. D, Particles and fields, 31(5), 1109-1113. https://doi.org/10.1103/physrevd.31.1109
Kaymakcalan, and Schechter. "Chiral Lagrangian of pseudoscalars and vectors." Physical review. D, Particles and fields vol. 31,5 (1985): 1109-1113. doi: https://doi.org/10.1103/physrevd.31.1109
Kaymakcalan Ö, Schechter J. Chiral Lagrangian of pseudoscalars and vectors. Phys Rev D Part Fields. 1985 Mar 01;31(5):1109-1113. doi: 10.1103/physrevd.31.1109. PMID: 9955803.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries